AllianceBernstein’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.66M Buy
135,940
+1,680
+1% +$29K ﹤0.01% 1843
2025
Q4
$2.63M Buy
134,260
+27,580
+26% +$522K ﹤0.01% 1851
2025
Q3
$1.35M Buy
106,680
+8,440
+9% +$96.3K ﹤0.01% 2207
2025
Q2
$935K Sell
98,240
-69,385
-41% -$764K ﹤0.01% 2333
2025
Q1
$1.75M Buy
167,625
+14,407
+9% +$206K ﹤0.01% 1975
2024
Q4
$3.61M Sell
153,218
-30,993
-17% -$917K ﹤0.01% 1647
2024
Q3
$6.62M Sell
184,211
-71,154
-28% -$2.83M ﹤0.01% 1393
2024
Q2
$9.01M Buy
255,365
+87,014
+52% +$2.53M ﹤0.01% 1219
2024
Q1
$4.78M Sell
168,351
-111,763
-40% -$2.53M ﹤0.01% 1482
2023
Q4
$3.73M Buy
280,114
+29,128
+12% +$285K ﹤0.01% 1630
2023
Q3
$2.25M Sell
250,986
-114,839
-31% -$1.24M ﹤0.01% 1812
2023
Q2
$4.12M Buy
365,825
+37,713
+11% +$445K ﹤0.01% 1514
2023
Q1
$3.78M Buy
328,112
+13,524
+4% +$176K ﹤0.01% 1515
2022
Q4
$3.65M Buy
314,588
+46,063
+17% +$533K ﹤0.01% 1574
2022
Q3
$3.41M Buy
268,525
+19,894
+8% +$228K ﹤0.01% 1574
2022
Q2
$1.71M Buy
248,631
+65,331
+36% +$450K ﹤0.01% 2043
2022
Q1
$1.77M Buy
+183,300
New +$1.56M ﹤0.01% 2160

Other funds holding DYN

AllianceBernstein's DYN Position: Q1 2026 in Review

AllianceBernstein increased its Dyne Therapeutics (DYN) stake by 1.3% in Q1 2026, buying an estimated $29K and bringing the position to 135,940 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1843.

AllianceBernstein first reported a position in DYN in Q1 2022 and has held it in 17 quarters since. The position peaked at $9.01M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • AllianceBernstein held 135,940 shares of Dyne Therapeutics worth $2.66M as of Q1 2026.
  • AllianceBernstein bought 1,680 Dyne Therapeutics shares in Q1 2026, an estimated $29K.
  • Dyne Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1843 holding.
  • AllianceBernstein first reported a position in Dyne Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • AllianceBernstein's Dyne Therapeutics position peaked at $9.01M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.